# Koichi Ichimura

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/koichi-ichimura/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,395 |
| Field | Glioma Diagnosis and Treatment |
| h-index | 68 |
| i10-index | 225 |
| Last Known Institution | Kyorin University |
| OpenAlex ID | https://openalex.org/A5083342160 |
| ORCID iD | https://orcid.org/0000-0002-3851-2349 |
| Works | 629 |

## Researcher papers

- [A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas](https://scholariq.org/papers/a-combination-of-tert-promoter-mutation-and-mgmt-methylation-status-predicts/)
- [Recurrent mutations of <scp><i>CD79B</i></scp> and <scp><i>MYD88</i></scp> are the hallmark of primary central nervous system lymphomas](https://scholariq.org/papers/recurrent-mutations-of-scp-i-cd79b-i-scp-and-scp-i-myd88-i-scp-are-the-hallmark/)
- [Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors](https://scholariq.org/papers/significance-of-molecular-classification-of-ependymomas-c11orf95-rela-fusion/)

## Researcher topics

- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Kyorin University](https://scholariq.org/institutions/kyorin-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.